Creative Biolabs Launched a Brand New Antibody Design and Conjugation Service
Recently, Creative Biolabs, a global biology company that provides high-quality antibody products, announced today their comprehensive antibody conjugation service, intending to become the best companion in custom ADC field.
An antibody drug conjugation generally consists of 3 parts as follows: a monoclonal antibody, the payload, and the linker, in which the antibody is the key for target specificity and serves as the cargo to deliver the cytotoxic drug (payload). A payload can be attached to different sites on an antibody in the use of diverse conjugation chemistry.
“However, we all know that it’s not easy to achieve more precisely controlled site-directed conjugations and subsequently a narrower distribution of drug-to-antibody ratio (DAR). We made a great effort to complete this complicated and difficult task by engineering special moieties with unique conjugation chemistries into antibody sequences in our antibody design services.” A scientist from Creative Biolabs said that.
“We incorporate Cysteine residues into defined sites on an antibody to create thiol-engineered antibody (EnCys-mAb) and conjugate payload drugs onto those Cysteine residues via thiol-based chemistry.”
Through antibody design, Creative Biolabs create a ‘cave’ on the desired locations on an antibody to facilitate meditope trapping and subsequently, achieve site-specific meditope-based conjugations. Taking advantage of the self-splicing inteins and engineer intein-fusion antibodies, they finally complete C-terminal specific antibody modification and yielding conjugates with DARs at 1 or 2.
As an international cooperation, Creative Biolabs has established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with our customers and research partners to develop new medicines for a better, healthier world.
About Creative Biolabs
Established in 2004, Creative Biolabs is highly specialized in advanced antibody biochemistry and engineering. With more than a decade of exploration and expansion, our current research and service capacity covers the entire new drug discovery and development pipeline, ranging from early discovery, preclinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, we have established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with our customers and research partners to develop new medicines for a better, healthier world.